Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 9.0% in November

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 6,570,000 shares, an increase of 9.0% from the November 15th total of 6,030,000 shares. Approximately 16.2% of the company's stock are short sold. Based on an average daily trading volume, of 807,000 shares, the short-interest ratio is presently 8.1 days.

Institutional Trading of Checkpoint Therapeutics

Several large investors have recently added to or reduced their stakes in the company. PVG Asset Management Corp lifted its holdings in shares of Checkpoint Therapeutics by 9.2% during the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company's stock worth $336,000 after purchasing an additional 12,676 shares during the period. Virtu Financial LLC purchased a new position in Checkpoint Therapeutics during the 3rd quarter worth approximately $30,000. Geode Capital Management LLC lifted its stake in Checkpoint Therapeutics by 41.2% during the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company's stock valued at $958,000 after acquiring an additional 124,787 shares during the period. State Street Corp boosted its holdings in shares of Checkpoint Therapeutics by 32.2% in the 3rd quarter. State Street Corp now owns 94,424 shares of the company's stock valued at $212,000 after acquiring an additional 23,000 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Checkpoint Therapeutics in the 3rd quarter valued at $148,000. Hedge funds and other institutional investors own 22.00% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CKPT. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a research report on Monday. Lake Street Capital boosted their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday.

Checkpoint Therapeutics Price Performance

NASDAQ:CKPT traded down $0.28 during trading hours on Monday, hitting $3.39. 16,494,230 shares of the company were exchanged, compared to its average volume of 624,046. Checkpoint Therapeutics has a 52-week low of $1.36 and a 52-week high of $4.50. The stock has a market capitalization of $165.53 million, a price-to-earnings ratio of -1.84 and a beta of 1.34. The company's 50 day moving average price is $3.50 and its 200-day moving average price is $2.67.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.08). On average, equities analysts predict that Checkpoint Therapeutics will post -0.91 earnings per share for the current year.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.